综述

影响RNA剪接的基因变异

展开
  • 山东大学实验畸形学教育部重点实验室,山东大学基础医学院医学遗传学系,济南 250012
邹永新,博士,副教授,研究方向:致病基因的分子机制。E-mail: zouyongxin@sdu.edu.cn|龚瑶琴,博士,教授,研究方向:致病基因的克隆及功能研究。E-mail: yxg8@sdu.edu.cn

收稿日期: 2016-10-08

  修回日期: 2016-12-02

  网络出版日期: 2016-12-07

基金资助

山东省自然科学基金重点项目(转化医学专题)资助(ZR2015HZ002)

Aberrant RNA splicing as the molecular basis of some pathogenic variants

Expand
  • The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, Shandong University School of Basic Medical Sciences, Ji?nan 250012, China

Received date: 2016-10-08

  Revised date: 2016-12-02

  Online published: 2016-12-07

Supported by

the Key Program of Shandong Provincial Natural Science Foundation, China(ZR2015HZ002)

摘要

发现和正确解读疾病相关突变是遗传病分子诊断和临床指导的关键。尽管二代测序技术的应用显著改善了突变检测效率,但解读突变的生物学效应仍然存在挑战。目前对基因检测结果的解读更多地关注突变对蛋白质结构和功能的影响,而忽视了基因变异对RNA剪接的影响。越来越多的证据显示引起RNA剪接异常的基因变异在疾病发生中发挥重要作用。本文对影响RNA剪接的主要突变类型和确认方法进行介绍,以期为准确判断突变的遗传效应提供参考。

本文引用格式

邹永新,龚瑶琴 . 影响RNA剪接的基因变异[J]. 遗传, 2017 , 39(3) : 200 -207 . DOI: 10.16288/j.yczz.16-336

Abstract

Identification and correct classification of disease-associated mutations are essential for molecular diagnosis and clinical management of many genetic disorders. Although next-generation sequencing has greatly accelerated the detection of nucleotide changes, the biological interpretation of most variants has become a real challenge. Moreover, attention is typically paid to protein-coding changes and the potential impact of exonic variants on RNA splicing is often ignored. There is increasing evidence showing that disease-causing aberrant RNA splicing is more widespread than currently appreciated. Here, we review the major types of the variants involved in RNA splicing and the approaches used to identify and characterize these variants. We hope to provide a reference for evaluation of the effects of mutations on diseases.

参考文献

[1] Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet, 2016, 53(3): 145-151.
[2] Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer, 2007, 121(2): 225-231.
[3] Padgett RA. New connections between splicing and human disease. Trends Genet, 2012, 28(4): 147-154.
[4] Ars E, Serra E, García J, Kruyer H, Gaona A, Lázaro C, Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet, 2000, 9(2): 237-247.
[5] Soukarieh O, Gaildrat P, Hamieh M, Drouet A, Baert-Desurmont S, Frébourg T, Tosi M, Martins A. Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools. PLoS Genet, 2016, 12(1): e1005756.
[6] Daguenet E, Dujardin G, Valcárcel J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep, 2015, 16(12): 1640-1655.
[7] Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med, 2012, 18(8): 472-482.
[8] Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Mu?oz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol, 2013, 14(3): 153-165.
[9] Svenson IK, Ashley-Koch AE, Gaskell PC, Riney TJ, Cumming WJK, Kingston HM, Hogan EL, Boustany RMN, Vance JM, Nance MA, Pericak-Vance MA, Marchuk DA. Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. Am J Hum Genet, 2001, 68(5): 1077-1085.
[10] Teraoka SN, Telatar M, Becker-Catania S, Liang T, ?nengüt S, Tolun A, Chessa L, Sanal ?, Bernatowska E, Gatti RA, Concannon P. Splicing defects in the ataxia-telangiectasia gene,ATM: underlying mutations and consequences. Am J Hum Genet, 1999, 64(6): 1617-1631.
[11] Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GM. A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet, 1998, 62(3): 713-715.
[12] Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet, 2001, 27(1): 55-58.
[13] Messiaen L, Callens T, De Paepe A, Craen M, Mortier G. Characterisation of two different nonsense mutations, C6792A and C6792G, causing skipping of exon 37 in the NF1 gene. Hum Genet, 1997, 101(1): 75-80.
[14]
文章导航

/